Skip to main content

Table 1 Patient and transplant characteristics

From: Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation

Characteristics  n = 63
Patient age, median (range), y 42 (16–65)
Diagnosis at transplant, no. (%)
Malignant diseases
  Acute myeloid leukemia 23 (36.5%)
  Chronic myeloid leukemia 9 (14.3%)
  Acute lymphoblastic leukemia 9 (14.3%)
  Chronic lymphocytic leukemia 4 (6.3%)
  Multiple myeloma 2 (3.2%)
  Non-Hodgkin lymphoma 3 (4.8%)
  Hodgkin lymphoma 2 (3.2%)
  Myelodysplastic syndrome 4 (6.3%)
Non-malignant diseases
  Severe aplastic anemia 4 (6.3%)
  Paroxysmal nocturnal hemoglobinuria 3 (4.8%)
Donor age, median (range), y 39 (6–65)
Patient gender (donor/recipient), n. (%)
  Male/male 23 (36.5%)
  Male/female 10 (15.9%)
  Female/male 13 (20.6%)
  Female/female 17 (27%)
Donor type, no. (%)
  HLA-identical related 61 (96.8%)
  HLA-matched unrelated 2 (3.2%)
Conditioning regimen, no. (%)
  High dose 46 (73%)
  Low dose 17 (27%)
Source of stem cells, no. (%)
  Bone marrow 23 (36.5%)
  Mobilized blood 40 (63.5%)
GVHD prophylaxis, no. (%)
  Cyclosporine plus methotrexate 49 (77.7%)
  Cyclosporine plus mycophenolate mofetil 14 (22.3%)
Acute GVHD, no. (%) 17 (27%)
  Grade 0-I 46 (73%)
  Grade II-IV 17 (27%)
Donor/recipient CMV serologic status, n° (%)
  IgG +/IgG+ 55 (87.2%)
  IgG +/IgG - 3 (4.8%)
  IgG -/IgG - 2 (3.2%)
  IgG-/igG+ 2 (3.2%)
  Not determined 1 (1.6%)
  1. GVDH graft-versus-host disease, CMV cytomegalovirus.